Equities Analysts Offer Predictions for JSPR FY2029 Earnings

Jasper Therapeutics, Inc. (NASDAQ:JSPR) – Stock analysts at HC Wainwright issued their FY2029 EPS estimates for Jasper Therapeutics in a research report issued on Wednesday, January 8th. HC Wainwright analyst E. Bodnar expects that the company will earn ($10.81) per share for the year. HC Wainwright currently has a “Buy” rating and a $40.00 price objective on the stock. The consensus estimate for Jasper Therapeutics’ current full-year earnings is ($4.47) per share.

Several other equities analysts have also issued reports on JSPR. BMO Capital Markets assumed coverage on shares of Jasper Therapeutics in a report on Friday, December 6th. They issued an “outperform” rating and a $63.00 price target on the stock. Royal Bank of Canada reduced their target price on Jasper Therapeutics from $68.00 to $48.00 and set an “outperform” rating on the stock in a research report on Thursday. Finally, JMP Securities reissued a “market outperform” rating and issued a $70.00 price target on shares of Jasper Therapeutics in a report on Monday, January 6th. Ten investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $67.75.

Jasper Therapeutics Stock Up 0.9 %

NASDAQ JSPR opened at $7.05 on Friday. Jasper Therapeutics has a 52 week low of $6.57 and a 52 week high of $31.01. The company has a 50 day moving average price of $21.37 and a 200 day moving average price of $20.27. The firm has a market cap of $105.76 million, a PE ratio of -1.49 and a beta of 2.18.

Institutional Investors Weigh In On Jasper Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. JPMorgan Chase & Co. raised its position in Jasper Therapeutics by 239.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 16,391 shares of the company’s stock worth $308,000 after buying an additional 11,567 shares during the last quarter. Barclays PLC increased its stake in shares of Jasper Therapeutics by 320.7% in the third quarter. Barclays PLC now owns 16,146 shares of the company’s stock worth $304,000 after acquiring an additional 12,308 shares during the period. Jane Street Group LLC purchased a new position in shares of Jasper Therapeutics during the third quarter worth $251,000. Wellington Management Group LLP acquired a new position in Jasper Therapeutics during the third quarter valued at $447,000. Finally, State Street Corp boosted its holdings in Jasper Therapeutics by 12.3% in the third quarter. State Street Corp now owns 214,883 shares of the company’s stock valued at $4,042,000 after purchasing an additional 23,564 shares during the last quarter. Institutional investors and hedge funds own 79.85% of the company’s stock.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.